Provided by Tiger Trade Technology Pte. Ltd.

NanoViricides

1.25
+0.01000.81%
Volume:331.84K
Turnover:427.00K
Market Cap:31.87M
PE:-2.87
High:1.33
Open:1.30
Low:1.24
Close:1.24
52wk High:2.23
52wk Low:0.8500
Shares:25.50M
Float Shares:24.90M
Volume Ratio:2.74
T/O Rate:1.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4355
EPS(LYR):-0.6263
ROE:-89.97%
ROA:-50.46%
PB:3.48
PE(LYR):-2.00

Loading ...

NanoViricides provides updateon Measles Drug Treatment Program

TIPRANKS
·
Yesterday

NanoViricides Drafts Phase II Trial Protocol for NV-387 Measles Treatment

Reuters
·
Yesterday

NanoViricides registers to sell 2.52M shares of common stock for holders

TIPRANKS
·
Aug 22

NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’

TIPRANKS
·
Aug 18

NanoViricides Wins DRC Acorep Clearance for Phase II NV-387 Ebola Treatment Trial

Reuters
·
Aug 18

NanoViricides, Inc: Received Regulatory Approval for a Phase Ii Clinical Trial of Nv-387 Oral Gummies as a Treatment for Ebola in DR Congo

THOMSON REUTERS
·
Aug 10

NanoViricides Wins DRC Approval for Phase II Trial of NV-387 Oral Gummies for Ebola Treatment

Reuters
·
Aug 10

NanoViricides Announces $3.8 Million Registered Direct Offering

TIPRANKS
·
Jul 30

NanoViricides Issues Warrants Exercisable at Us$1.75 in Us$3.8 Million Registered Direct Offering

Reuters
·
Jul 30

NanoViricides Raises Financing for Trial of Ebola Treatment, Awaits Regulatory Approval in Congo

MT Newswires Live
·
Jul 28

NanoViricides awaits regulatory approval to being Phase II trial of NV-387

TIPRANKS
·
Jul 28

NanoViricides Shares Fall Pre-Bell After $3.8 Million Direct Stock Sale Pricing

MT Newswires Live
·
Jul 24

NanoViricides prices $3.8M registered direct offering

TIPRANKS
·
Jul 24

Nanoviricides Prices Offering with 2,516,339 Warrants at US$ 1.75 Exercise Price

Reuters
·
Jul 24

NanoViricides applies for ACOREP approval to begin Phase II NV-387 trial

TIPRANKS
·
Jul 22

Nanoviricides Seeks DR Congo Regulator Clearance for Phase II Ebola Trial of Nv-387 Oral Gummies

Reuters
·
Jul 22

Nanoviricides, Inc - Applied to Acorep for Approval to Begin Phase Ii Clinical Trial of Nv-387 Oral Gummies as Treatment for Bundibugyo Ebolavirus

THOMSON REUTERS
·
Jul 22

Nanoviricides, Inc: Sufficient Quantity of Nv-387 Oral Gummies Drug Product for Starting Clinical Trial Against Ebola is Already Available in Drc

THOMSON REUTERS
·
Jul 22

NanoViricides Establishes ATM Equity Sales Agreement

TIPRANKS
·
Jul 18

Nanoviricides Wins DRC Ethics Approval for Phase II Trial of Nv-387 Oral Gummies for Ebola

Reuters
·
Jul 13